Larimar Therapeutics (LRMR) pipeline and stated timing

Name in SEC filings: Larimar Therapeutics, Inc.

Pipeline at a glance

Program	Event	Stage	Stated timing	Filing
nomlabofusp	submission	—	second half of 2026	10-Q · Aug 4, 2026

Source: ORION, orionbiotechai.com/company/LRMR, data as of Oct 18, 2026
https://www.orionbiotechai.com/company/LRMR

Nearest upcoming stated timing: nomlabofusp · NDA/BLA submission · second half of 2026

SEC sources last checked Oct 18, 2026.

Programs and stated timing

○ Quote matched to filing (not yet reviewed by founder) · ✓ Checked by founder.

nomlabofusp

Matched

NDA/BLA submissionsecond half of 2026

Stage: —

Public float: $94,670,955 · as of Jun 30, 2025 · SEC filing

We initiated our rolling BLA submission to the FDA for marketing approval of nomlabofusp using the accelerated approval pathway and expect to submit the remaining modules in the second half of 2026

10-Q · Filed Aug 4, 2026 · Last checked Oct 18, 2026

Source details

Accession 0001193125-26-331529

Alert me · Calendar: same stage and window-end month (2026-12)

How this date was described over time

Company periods and sentences are quoted as written. A matching disclosure uses the SEC filing date for the same program and event type. As of Oct 19, 2026.

Program / event	Stated period and SEC wording	Disclosure in stated period
nomlabofuspSubmission	second half of 2026 “We initiated our rolling BLA submission to the FDA for marketing approval of nomlabofusp using the accelerated approval pathway and expect to submit the remaining modules in the second half of 2026” Filed Aug 4, 2026 · 10-Q	Still within period As of Oct 19, 2026
nomlabofuspSubmission	second half of 2026 “the remaining modules are expected to be submitted in the second half of 2026.” Filed Jun 29, 2026 · EX-99.1	Still within period As of Oct 19, 2026
nomlabofuspSubmission	2026 “Submission of final modules for rolling BLA submission expected 2H 2026” Filed Jun 29, 2026 · EX-99.1	Not compared ORION has no confirmed start and end dates for this wording, so it is not compared with filings.
nomlabofuspSubmission	second half of 2026 “We are continuing to focus on the completeness of our chemistry, manufacturing and controls ("CMC") module, and plan to submit the final modules, including the CMC module, in the second half of 2026.” Filed May 14, 2026 · 10-Q	Still within period As of Oct 19, 2026
nomlabofuspSubmission	second half of 2026 “plan to submit the CMC portion of the BLA in the second half of 2026” Filed May 14, 2026 · EX-99.1	Still within period As of Oct 19, 2026
nomlabofuspSubmission	second half of 2026 “submission of the final modules including the CMC module expected in second half of 2026.” Filed May 14, 2026 · EX-99.1	Still within period As of Oct 19, 2026
nomlabofuspSubmission	June 2026 “We are targeting nomlabofusp BLA submission in June 2026 seeking accelerated approval using tissue FXN levels as a novel surrogate endpoint.” Filed Mar 19, 2026 · 10-K	Not compared ORION has no confirmed start and end dates for this wording, so it is not compared with filings.
nomlabofuspSubmission	second quarter of 2026 “We plan to submit a BLA seeking accelerated approval in the second quarter of 2026.” Filed Nov 5, 2025 · 10-Q	Not compared ORION has no confirmed start and end dates for this wording, so it is not compared with filings.
nomlabofuspSubmission	second quarter of 2026 “In the second quarter of 2026, we plan to submit a BLA seeking accelerated approval.” Filed Aug 14, 2025 · 10-Q	Not compared ORION has no confirmed start and end dates for this wording, so it is not compared with filings.

“Not compared” means ORION has not matched this wording against a complete set of SEC filings for its period. It says nothing either way about whether a matching filing exists. Wording without exact dates is not given calendar dates.

Watch LRMR

Or email ORION to ask for this Watch.

Request another SEC timing statement

Suggest an SEC timing statement to add for LRMR. You can include the original filing link in your note. The founder reads each request by hand.

Or email ORION.

Reading these records

First stated window: The timing wording in the earliest company statement located within the sources checked, quoted as written (for example “2H 2026”). An earlier statement may exist outside those sources.
Disclosure date: The date of the filing or company release that disclosed the readout. “None found” means no such disclosure was located in the sources checked. SEC filings were searched through the “SEC filings searched through” date shown.
1H, 2H, 1Q–4Q: First or second half, or first to fourth quarter, of the year named, as the company wrote it. Equivalent notations are compared together; the original wording stays visible.
SEC original: The filing as published on the SEC EDGAR system. “Company original” is the release on the company's own investor site.
Status: One of seven labels set by founder review of the original filings. Definitions: Methodology.

See LRMR in the calendar · Review labels and methodology